Somatosensory Disorders: Clinical Trials

17 trials for Somatosensory Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 3 unknown, 1 active not recruiting, 1 terminated. 17 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Completed 12, Unknown 3, Active not recruiting 1, Terminated 1
Phase 22Completed 1, Unknown 1

Follow Somatosensory Disorders: new trials by email Literature Review of Somatosensory Disorders trials Research Report on Somatosensory Disorders

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Lacosamide - Chronic Pain, Chronic Pain Syndrome
Phase 1Active not recruitingIndiana University212023-03-172026-06-03
Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers
Pulmodexane® 30mg, lactose - Experimental Pain, Hyperalgesia
Phase 1CompletedUniversity Hospital, Clermont-Ferrand202015-11-012026-08-06
Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers
Fenobam, Placebo - Hyperalgesia, Allodynia
Phase 1CompletedLaura Cavallone332014-01-012016-04-29
Effect of High Dose Naloxone on Secondary Hyperalgesia
Naloxone (2 mg/kg), Placebo - Hyperalgesia, Pain
Phase 1CompletedCopenhagen University Hospital, Rigshospitalet152013-06-012014-02-25
Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models
Tapentadol immediate release, placebo - Pain, Hyperalgesia
Phase 1TerminatedUniversity Hospital Schleswig-Holstein242012-10-012022-09-14
Hyperalgesia and Pain
Nitrous Oxide - Hyperalgesia
Phase 1CompletedAir Liquide Santé International202012-01-012025-09-11
Gabapentin and Donepezil Combination on Experimental Human Pain Models
Gabapentin lower dose, Donepezil, Placebo (Dop) - Pain, Neuropathic
Phase 1CompletedGlaxoSmithKline482011-10-112017-06-12
Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers
AZD3161, Lidocaine, AZD3161 Placebo - Peripheral Neuropathic Pain, Nociceptive Pain
Phase 1CompletedAstraZeneca262010-12-012011-04-12
Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients
Milnacipran - Fibromyalgia
Phase 1CompletedUniversity of Florida512009-11-012014-07-31
A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers
Placebo, Oral NGX426 (Powder in solution) - Healthy, Hyperalgesia
Phase 1CompletedTorreyPines Therapeutics182008-05-012009-01-30
A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers
Duloxetine, GSK189254, GSK189254 Placebo - Hyperalgesia
Phase 1CompletedGlaxoSmithKline402006-10-022017-08-07
Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia
Lidoderm Patch - Pain, Hyperalgesia
Phase 1CompletedUniversity of California, San Diego122005-12-012006-09-08
Use of a Vibrotactile Sensory Prosthesis in Patients With Postural Imbalance and Spatial Disorientation
Vibrotactile feedback - Vestibular Diseases, Peripheral Neuropathies
Phase 1UnknownImperial College London302005-01-012016-11-11
Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy
Amantadine - Hyperalgesia, Pain
Phase 1 / Phase 2UnknownUniversity Health Network, Toronto1322004-01-012006-03-14
GW406381 In Patients With Peripheral Nerve Injury
GW406381 - Hyperalgesia, Neurodynia
Phase 1CompletedGlaxoSmithKline402003-09-012009-02-23
Hyperalgesia in Methadone Patients: Can it be Treated?
dextromethorphan - Opioid-induced Hyperalgesia
Phase 1UnknownNational Institute on Drug Abuse (NIDA)402002-09-012017-01-11
Analgesic Efficacy of Smoked Cannabis
Smoked Cannabis - Pain, Hyperalgesia
Phase 1 / Phase 2CompletedCenter for Medicinal Cannabis Research152002-02-012006-06-23

Narrower conditions

Hyperalgesia (16)  ·  Pain (10)  ·  Neuralgia (2)  ·  Chronic Pain (1)  ·  Digestive System Diseases (1)  ·  Fibromyalgia (1)  ·  Marijuana Abuse (1)  ·  Nociceptive Pain (1)  ·  Opioid-Related Disorders (1)  ·  Pancreatic Diseases (1)  ·  Pancreatitis (1)  ·  Pancreatitis, Chronic (1)  ·  Paresthesia (1)  ·  Perceptual Disorders (1)  ·  Peripheral Nerve Injuries (1)

Broader conditions

Nervous System Diseases (17)  ·  Neurologic Manifestations (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Sensation Disorders (17)  ·  Signs and Symptoms (17)  ·  Neuromuscular Diseases (4)  ·  Chemically-Induced Disorders (2)  ·  Mental Disorders (2)  ·  Pain (2)  ·  Peripheral Nervous System Diseases (2)  ·  Substance-Related Disorders (2)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Ear Diseases (1)

Interventions

Lidocaine (2)  ·  6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide (1)  ·  Amantadine (1)  ·  Dextromethorphan (1)  ·  Donepezil (1)  ·  Duloxetine Hydrochloride (1)  ·  GW406381X (1)  ·  Gabapentin (1)  ·  Lacosamide (1)  ·  Lactose (1)  ·  Milnacipran (1)  ·  Naloxone (1)  ·  Nitrous Oxide (1)  ·  Powders (1)  ·  Solutions (1)

Sponsors

GlaxoSmithKline (3)  ·  Air Liquide Santé International (1)  ·  AstraZeneca (1)  ·  Center for Medicinal Cannabis Research (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Imperial College London (1)  ·  Indiana University (1)  ·  Laura Cavallone (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  TorreyPines Therapeutics (1)  ·  University Health Network, Toronto (1)  ·  University Hospital Schleswig-Holstein (1)  ·  University Hospital, Clermont-Ferrand (1)  ·  University of California, San Diego (1)  ·  University of Florida (1)

Countries

United States (7)  ·  United Kingdom (5)  ·  Germany (2)  ·  Canada (1)  ·  Denmark (1)  ·  France (1)

Top investigators

Mark Wallace, M.D. (2)  ·  Adolfo M Bronstein, Pr, MD (1)  ·  Aynur Unalp-Arida, MD, PhD (1)  ·  Bo Fransson (1)  ·  Christopher Kennard, Pr, MD (1)  ·  Darren Wilbraham, MD, MBBS DCPSA (1)  ·  Joergen B Dahl, M.D., DMSc (1)  ·  Laura F Cavallone, M.D. (1)  ·  Lucia Gagliese, PhD (1)  ·  Mads U. Werner, M.D., Ph.D., DMSc (1)  ·  Margaret A Compton, RN, PhD (1)

Results publications

PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 15647484, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21412914, PMID 21765969, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24661411, PMID 24867013, PMID 25218827, PMID 25221944, PMID 25418676, PMID 25872113, PMID 25957198, PMID 25998206, PMID 26029937, PMID 26987082, PMID 27295489, PMID 27407096, PMID 28074005, PMID 28106092, PMID 28119481, PMID 28409480, PMID 28767350, PMID 29671994, PMID 29769209, PMID 30325859

NIH funding

2015 (1), R01DK132709 (1)